@article{CCO1232,
author = {Eric S. Kim and David J. Stewart and Alok A. Khorana},
title = {Can EGFR mutation status evolve with chemotherapy?},
journal = {Chinese Clinical Oncology},
volume = {2},
number = {1},
year = {2012},
keywords = {},
abstract = {Epidermal growth factor receptor (EGFR) inhibition by oral tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are important treatment strategies for advanced non-small-cell lung cancer (NSCLC). However, a significant number of patients have tumors that are intrinsically resistant to chemotherapy and/or TKIs, and even those who respond initially eventually develop acquired resistance.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/1232}
}